| dbo:abstract |
Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) is an analog of LSD developed by the team led by David E. Nichols at Purdue University. It was developed as a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor. There are three possible stereoisomers around the azetidine ring, with the (S,S)-(+) isomer being the most active, slightly more potent than LSD itself in drug discrimination tests using trained rats. There have been several unconfirmed reports of lysergic acid 2,4-dimethylazetidide being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "diazedine" and "λ". In 2013 LSZ also appeared on some designer drug and research chemical markets in the UK. LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012. (en) |
| dbo:casNumber |
470666-31-0 470666-32-1 |
| dbo:fdaUniiCode |
8SWJ525W4R |
| dbo:pubchem |
71301249 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/LSD-azetidine.svg?width=300 |
| dbo:wikiPageExternalLink |
http://www.legislation.gov.uk/uksi/2014/3271/made |
| dbo:wikiPageID |
19909799 (xsd:integer) |
| dbo:wikiPageLength |
7959 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1084857332 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Potency_(pharmacology) dbr:Purdue_University dbr:David_E._Nichols dbc:Azetidines dbc:Designer_drugs dbc:Serotonin_receptor_agonists dbr:Lysergic_acid_diethylamide dbr:Chirality_(chemistry) dbr:Stereoisomer dbr:Functional_analog_(chemistry) dbr:1P-ETH-LAD dbr:1P-LSD dbr:1V-LSD dbr:Azetidine dbr:AL-LAD dbr:ALD-52 dbr:Advisory_Council_on_the_Misuse_of_Drugs dbr:5-HT2A_receptor dbr:ETH-LAD dbr:PRO-LAD dbr:Receptor_(biochemistry) dbr:1B-LSD dbr:1cP-LSD dbc:Lysergamides dbc:Psychedelia dbr:LSM-775 dbr:Lambda dbr:O-Acetylpsilocin dbr:UK_Misuse_of_Drugs_Act dbr:Blotter_paper dbr:1cP-AL-LAD |
| dbp:c |
21 (xsd:integer) |
| dbp:casNumber |
470666 (xsd:integer) |
| dbp:chemspiderid |
30773535 (xsd:integer) |
| dbp:h |
25 (xsd:integer) |
| dbp:index2Comment |
-isomer, tartrate salt (en) |
| dbp:index2Label |
tartrate salt (en) |
| dbp:indexComment |
-isomer, freebase (en) |
| dbp:indexLabel |
freebase (en) |
| dbp:iupacName |
[-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-[-2,4-dimethylazetidin-1-yl]methanone (en) |
| dbp:legalDe |
NpSG (en) |
| dbp:legalStatus |
Illegal in Denmark, France, Sweden and Switzerland (en) |
| dbp:legalUk |
Class A (en) |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
71301249 (xsd:integer) |
| dbp:routesOfAdministration |
Oral (en) |
| dbp:smiles |
C[C@H]1C[C@@H]C (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
DUKNIHFTDAXJON-CTQRGLTFSA-N (en) |
| dbp:synonyms |
Lysergic acid 2,4-dimethylazetidine, Diazedine, Lambda, LSZ (en) |
| dbp:unii |
8 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
452018128 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:width |
130 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Hallucinogens dbt:Redirect dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Fdacite dbt:Stdinchicite dbt:Ergolines |
| dcterms:subject |
dbc:Azetidines dbc:Designer_drugs dbc:Serotonin_receptor_agonists dbc:Lysergamides dbc:Psychedelia |
| gold:hypernym |
dbr:Analog |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Agent114778436 yago:CausalAgent100007347 yago:Communication100033020 yago:DesignerDrug103179489 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 yago:PsychoactiveDrug104017137 dbo:Drug yago:Statement106722453 yago:Substance100020090 yago:WikicatDesignerDrugs umbel-rc:DrugProduct |
| rdfs:comment |
Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) is an analog of LSD developed by the team led by David E. Nichols at Purdue University. It was developed as a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor. There are three possible stereoisomers around the azetidine ring, with the (S,S)-(+) isomer being the most active, slightly more potent than LSD itself in drug discrimination tests using trained rats. (en) |
| rdfs:label |
Lysergic acid 2,4-dimethylazetidide (en) |
| owl:sameAs |
freebase:Lysergic acid 2,4-dimethylazetidide yago-res:Lysergic acid 2,4-dimethylazetidide wikidata:Lysergic acid 2,4-dimethylazetidide dbpedia-sh:Lysergic acid 2,4-dimethylazetidide dbpedia-sr:Lysergic acid 2,4-dimethylazetidide https://global.dbpedia.org/id/4qnmj |
| prov:wasDerivedFrom |
wikipedia-en:Lysergic_acid_2,4-dimethylazetidide?oldid=1084857332&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/LSD-azetidine.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Lysergic_acid_2,4-dimethylazetidide |
| is dbo:wikiPageRedirects of |
dbr:Diazedine dbr:LA-SS-Az dbr:LSZ dbr:Lysergic_acid_2,4-dimethylazetidine |
| is dbo:wikiPageWikiLink of |
dbr:David_E._Nichols dbr:List_of_psychedelic_drugs dbr:Lysergamides dbr:Lysergic_acid_2-butyl_amide dbr:1P-LSD dbr:2,5-Dimethoxy-4-iodoamphetamine dbr:AL-LAD dbr:ALD-52 dbr:5-HT1A_receptor dbr:ETH-LAD dbr:1B-LSD dbr:1cP-LSD dbr:LSD-Pip dbr:LSM-775 dbr:C21H25N3O dbr:Diazedine dbr:TNF_inhibitor dbr:LA-SS-Az dbr:LSZ dbr:Lysergic_acid_2,4-dimethylazetidine |
| is foaf:primaryTopic of |
wikipedia-en:Lysergic_acid_2,4-dimethylazetidide |
